ゼリア新薬工業の株価時系列
日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
---|---|---|---|---|---|---|---|
2023/01/25 | 2,172 | 2,188 | 2,164 | 2,180 | +16 | +0.7% | 39,100 |
2023/01/24 | 2,148 | 2,170 | 2,138 | 2,164 | +12 | +0.6% | 38,600 |
2023/01/23 | 2,143 | 2,160 | 2,143 | 2,152 | +11 | +0.5% | 23,400 |
2023/01/20 | 2,116 | 2,147 | 2,116 | 2,141 | +25 | +1.2% | 19,700 |
2023/01/19 | 2,130 | 2,134 | 2,115 | 2,116 | -20 | -0.9% | 27,000 |
2023/01/18 | 2,115 | 2,154 | 2,115 | 2,136 | +24 | +1.1% | 28,100 |
2023/01/17 | 2,116 | 2,123 | 2,104 | 2,112 | +8 | +0.4% | 24,000 |
2023/01/16 | 2,086 | 2,118 | 2,085 | 2,104 | +11 | +0.5% | 24,100 |
2023/01/13 | 2,095 | 2,110 | 2,089 | 2,093 | -5 | -0.2% | 40,300 |
2023/01/12 | 2,094 | 2,104 | 2,077 | 2,098 | +4 | +0.2% | 54,700 |
2023/01/11 | 2,092 | 2,121 | 2,092 | 2,094 | +3 | +0.1% | 48,300 |
2023/01/10 | 2,130 | 2,142 | 2,090 | 2,091 | -39 | -1.8% | 54,500 |
2023/01/06 | 2,136 | 2,138 | 2,116 | 2,130 | -7 | -0.3% | 39,400 |
2023/01/05 | 2,154 | 2,161 | 2,121 | 2,137 | -29 | -1.3% | 51,500 |
2023/01/04 | 2,256 | 2,256 | 2,166 | 2,166 | -97 | -4.3% | 48,100 |
2022/12/30 | 2,266 | 2,296 | 2,263 | 2,263 | -18 | -0.8% | 30,500 |
2022/12/29 | 2,251 | 2,284 | 2,237 | 2,281 | +30 | +1.3% | 40,700 |
2022/12/28 | 2,237 | 2,253 | 2,226 | 2,251 | +5 | +0.2% | 38,100 |
2022/12/27 | 2,235 | 2,258 | 2,225 | 2,246 | +15 | +0.7% | 24,000 |
2022/12/26 | 2,254 | 2,254 | 2,227 | 2,231 | -15 | -0.7% | 16,900 |
2022/12/23 | 2,247 | 2,261 | 2,232 | 2,246 | -13 | -0.6% | 26,500 |
2022/12/22 | 2,247 | 2,269 | 2,237 | 2,259 | +22 | +1% | 42,400 |
2022/12/21 | 2,247 | 2,258 | 2,219 | 2,237 | -19 | -0.8% | 55,100 |
2022/12/20 | 2,284 | 2,299 | 2,193 | 2,256 | -21 | -0.9% | 53,600 |
2022/12/19 | 2,264 | 2,284 | 2,258 | 2,277 | +17 | +0.8% | 44,900 |
2022/12/16 | 2,300 | 2,309 | 2,260 | 2,260 | -42 | -1.8% | 112,400 |
2022/12/15 | 2,314 | 2,340 | 2,300 | 2,302 | -26 | -1.1% | 26,000 |
2022/12/14 | 2,300 | 2,334 | 2,293 | 2,328 | +34 | +1.5% | 83,000 |
2022/12/13 | 2,270 | 2,303 | 2,269 | 2,294 | +48 | +2.1% | 70,600 |
2022/12/12 | 2,219 | 2,253 | 2,211 | 2,246 | +3 | +0.1% | 33,500 |
2022/12/09 | 2,238 | 2,251 | 2,230 | 2,243 | ±0 | ±0% | 37,500 |
2022/12/08 | 2,223 | 2,249 | 2,213 | 2,243 | +27 | +1.2% | 64,400 |
2022/12/07 | 2,189 | 2,230 | 2,184 | 2,216 | +25 | +1.1% | 33,700 |
2022/12/06 | 2,155 | 2,200 | 2,155 | 2,191 | +8 | +0.4% | 44,700 |
2022/12/05 | 2,203 | 2,206 | 2,169 | 2,183 | -27 | -1.2% | 34,400 |
2022/12/02 | 2,240 | 2,247 | 2,192 | 2,210 | -48 | -2.1% | 78,900 |
2022/12/01 | 2,227 | 2,260 | 2,226 | 2,258 | +32 | +1.4% | 69,300 |
2022/11/30 | 2,242 | 2,245 | 2,224 | 2,226 | -16 | -0.7% | 50,400 |
2022/11/29 | 2,268 | 2,269 | 2,240 | 2,242 | -43 | -1.9% | 64,500 |
2022/11/28 | 2,295 | 2,297 | 2,268 | 2,285 | +6 | +0.3% | 37,500 |
2022/11/25 | 2,274 | 2,291 | 2,274 | 2,279 | +23 | +1% | 39,800 |
2022/11/24 | 2,266 | 2,280 | 2,255 | 2,256 | -7 | -0.3% | 52,700 |
2022/11/22 | 2,220 | 2,266 | 2,220 | 2,263 | +49 | +2.2% | 72,600 |
2022/11/21 | 2,200 | 2,221 | 2,195 | 2,214 | +23 | +1% | 41,700 |
2022/11/18 | 2,200 | 2,210 | 2,191 | 2,191 | -7 | -0.3% | 61,500 |
2022/11/17 | 2,163 | 2,199 | 2,163 | 2,198 | +31 | +1.4% | 39,900 |
2022/11/16 | 2,150 | 2,178 | 2,145 | 2,167 | +17 | +0.8% | 53,000 |
2022/11/15 | 2,162 | 2,169 | 2,150 | 2,150 | +13 | +0.6% | 28,000 |
2022/11/14 | 2,170 | 2,174 | 2,135 | 2,137 | -61 | -2.8% | 48,700 |
2022/11/11 | 2,223 | 2,225 | 2,183 | 2,198 | +5 | +0.2% | 45,200 |
451~
500
件表示中 / 3586件
類似銘柄と比較する
現在ご覧いただいている「ゼリア新薬」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
---|---|---|---|---|---|---|---|---|
ゼリア新薬 | 224,400円 | +13.6% | +29.2% | 2.05% | 11.64倍 | 1.12倍 |
|
製薬中堅。医療用は消化器系中心。滋養強壮剤「ヘパリーゼ」も柱。スイス企業買収で海外展開 |
鳥居薬 | 476,000円 | +12.0% | +28.1% | 2.52% | 26.24倍 | 1.11倍 |
|
JT傘下。柱の抗HIV薬販売権喪失後、自社製品の腎・透析、アレルゲン等の開発強化 |
持田薬 | 331,500円 | +3.0% | +27.5% | 2.41% | 20.99倍 | 0.91倍 |
|
医薬中堅。高脂血症薬、降圧薬など循環器系得意。婦人科系にも強み。消化器系育成。化粧品も |
ネクセラファーマ | 113,200円 | +197.7% | - | 0.00% | 46.26倍 | 1.48倍 |
|
創薬ベンチャー老舗。買収で成長。英国の創薬事業に日本が柱の後期治験・製造販売事業加わる |
杏林製薬 | 149,900円 | +3.2% | +4.5% | 3.47% | 17.22倍 | 0.66倍 |
|
医薬中堅。柱のぜんそく薬、呼吸器アレルギー薬は下期に比重。消化器領域育成。後発品も |
市場注目の銘柄
チャート関連のコラム